Yazar "Keser, Muhammed Furkan" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Effect of Rituximab Use on Hepatitis B Reactivation in Individuals with Resolved Hepatitis B Infection and Rheumatic Disease: A Single Center Study(Inonu University, 2024) Erdoğan, Esra; Erdoğan, Mehmet Ali; Yolbaş, Servet; Keser, Muhammed Furkan; Aydin, SalihaHepatitis B infection is a global disease with significant morbidity and mortality rates. This study aims to evaluate the frequency of HBV reactivation in patients with resolved HBV infection using rituximab for the treatment of various rheumatological diseases. Patients receiving rituximab therapy for the treatment of rheumatic diseases were retrospectively screened for serological HBV infection markers (HBV DNA, HBsAg, anti-HBc IgG and anti-HBs). Twenty-five patients with resolved HBV infection who were HBV DNA-negative, HBsAg-negative and anti-HBc IgG-positive were included in the study. Twenty-two patients were female (88%) and three were male (12%). The average age of the patients was 62.56±9.786 years. Out of 25 patients, 22 had rheumatoid disease, two had Sjögren's syndrome, and one patient had systemic lupus erythematosus. While anti-HBs was positive in 15 patients, anti-HBs was negative in 10 patients. The mean HBsAg titer of the patients before treatment was 0.27±0.102, while the anti-HBs titer was 211.00±317.380 IU/L. Hepatitis B reactivation was not observed in any of the patients included in the study. Hence, the data suggest that patients with rheumatological diseases have a low risk of reactivation of HBV infection under rituximab treatment. However, prospective, multicenter studies involving more patients are needed to reach definitive conclusions. © 2024, Inonu University. All rights reserved.Öğe Endoscopic removal of surgical sponges that are left in the abdomen during a surgical procedure(Mosby-Elsevier, 2026) Keser, Muhammed Furkan; Cagin, Yasir Furkan; Erdogan, Mehmet Ali; Orman, Ibrahim; Yildirim, Oguzhan; Seckin, Yuksel; Harputluoglu, Murat[No abstract available]Öğe The frequency of hepatitis B virus reactivation in patients receiving anti-TNF treatment: A single center, retrospective study(2024) Keser, Muhammed Furkan; Erdogan, Mehmet Ali; Bahçecioğlu, Ömer Faruk; Seçkin, Yüksel; Yolbaş, Servet; Yıldırım, Tülay; Yıldırım, OğuzhanAim: The equilibrium between the host immune response counter the hepatitis B virus (HBV) and the amount of viral replication is a crucial factor in the pathogenesis of HBVassociated liver disease. Tumor necrosis factor-alpha (TNF-?) is a considerable proinflammatory and immune regulatory cytokine in the pathogenesis of various inflammatory and autoimmune conditions. There is no consensus on using antiviral prophylaxis treatments in cases who have been exposed to hepatitis B but have not become chronically ill, and are thus planned to receive anti-TNF-? treatment. The aim of this study is to determine the frequency of reactivation after anti-TNF treatment in cases with isolated anti-HBc total positivity who have been exposed to hepatitis B virus. Materials and Methods: Serological HBV infection markers (HBsAg, anti-HBc IgG and anti-HBs) of 1467 adult cases who received anti-TNF therapy for the indications of various rheumatological diseases in the rheumatology and physical therapy clinics between the years 2010-2021 were retrospectively screened using the hospital’s electronic information system. Results: 140 rheumatologic disease cases who took a TNF-? inhibitor (infliximab, adalimumab, etanercept, golimumab, certolizumab) treatment were included in this study. Before the cases were started on TNF-? treatment, all cases were anti-HBc total positive, 110 were anti-HBs positive, 30 were anti-HBs negative, and 4 were HbsAg positive and HBV-DNA negative. The median pre-treatment anti-HBc total and anti-HBs values of the cases were 5.6 IU/L and 79.29 IU/L, respectively. No HBV reactivation was observed in any of the 140 cases after a median follow-up duration of 71.5 (min. 8, max. 185) months. Conclusion: In conclusion, HBV reactivation was not detected in any of the anti-HBc positive cases included in this study, which suggest that anti-HBc positive cases can be followed up with close follow-up without starting them on anti-TNF therapies and antiviral prophylaxis.Öğe Impact of reflux, bruxism, age, and plaque index on anterior tooth wear: A cross-sectional clinical evaluation(2025) Şimşek, Enis; Ocal, Fıkrı; Keser, Muhammed Furkan; Sarıcı, TubaAim: This study aims to evaluate the effect of variables such as gastroesophageal reflux disease (GERD), bruxism, plaque index, and age on erosive wear occurring on the palatal surfaces of maxillary anterior teeth, and to objectively measure this wear using the Anterior Clinical Erosive Classification (ACEC). Materials and Methods: A total of 507 individuals were included. Participants completed selfreport questionnaires regarding the presence, previous diagnosis, disease duration, and medication use. Bruxism was assessed through self-report and clinical examination. Erosive wear on maxillary anterior teeth palatal surfaces was measured using ACEC, and plaque accumulation using the Silness and Löe Plaque Index. Statistical analyses included independent sample t-tests and Spearman/Pearson correlation coefficients. Significance was set at p<0.05. Results: Reflux disease was detected in 20.9% of the participants in the study. ACEC scores of individuals reporting reflux symptoms were found to be significantly higher compared to healthy individuals (p<0.05). ACEC scores were also found to be significantly higher in individuals with bruxism than those of without bruxism. In contrast, the plaque index did not show a significant difference between the groups. Additionally, a significant and positive relationship was found between the duration of reflux and ACEC scores (r=0.281, p<0.01). ACEC scores were observed to be higher in individuals receiving reflux treatment compared to those not using medication. Conclusion: These findings indicate that reflux affects not only the gastrointestinal system but also oral and dental health and emphasize the importance of early diagnosis and intervention for dental erosion in individuals with reflux symptoms. Our study reveals the usability of the ACEC in large populations and sheds light on the multifactorial etiology of dental erosion. It also highlights the need to consider the potential abrasive effects of medications used in reflux treatment.Öğe Long-Term Post-transplant Outcomes in Patients with Hepatitis D Virus Infection at a High-Volume Liver Transplant Center(Springer, 2026) Keser, Muhammed Furkan; Keser, Zeynep Busra; Yurdaydin, Cihan; Yilmaz, Sezai; Harputluoglu, MuratBackground and Aims Hepatitis D virus (HDV) infection remains a major cause of liver failure in T & uuml;rkiye, yet post-transplant outcomes and recurrence predictors are not well defined. This study aimed to evaluate long-term outcomes and risk factors for HDV recurrence following liver transplantation in a high-volume transplant center. Methods We retrospectively analyzed 182 patients who underwent liver transplantation for HDV-related liver disease between 2010 and 2024. Clinical, virological, and survival data were compared between patients with and without HDV recurrence. Kaplan-Meier survival and Cox regression analyses were performed to identify independent predictors of recurrence. Results HDV recurrence occurred in 12 patients (6.6%) during a median follow-up of 80 months. HBIG administration significantly reduced recurrence risk (HR = 0.001, p < 0.001), while post-transplant HBV recurrence was strongly associated with HDV relapse (p < 0.001). Pre-transplant hepatocellular carcinoma (HCC) showed no significant association with HDV recurrence. Overall survival did not differ significantly between recurrence and non-recurrence groups (p = 0.068). Conclusions Our results showed that HDV recurrence was infrequent and was not associated with a statistically significant difference in post-transplant survival. Post-transplant HBV recurrence and HBIG therapy were identified as the main factors influencing HDV recurrence. Another important finding was that pre-transplant hepatocellular carcinoma (HCC) was not significantly associated with HDV recurrence. These results provide valuable long-term evidence from an HDV-endemic region and may guide post-transplant management strategies.Öğe Long-term results of celiac disease patients who underwent liver transplantation(Kare Publ, 2025) Altun, Caner; Saglam, Osman; Keser, Muhammed Furkan; Ataman, Engin; Efe, Cumali Savas; Burkek, Hilal; Yilmaz, SezaiBackground and Aim: Although there are a few studies reporting transplantation for celiac disease (CD), there are no studies reporting long-term outcomes after transplantation in CD patients. Therefore, we aimed to report the long-term outcomes of patients who underwent liver transplantation (LT) for CD in our high-volume liver transplantation center. Materials and Methods: Our study was a single-center, retrospective study and included 28 CD patients who underwent LT at Inonu University. CD diagnosis was made based on anti-tissue transglutaminase or anti-endomysium antibody positivity and/or duodenal biopsy results. Results: The 1-, 3-, 5-, and 10-year survival rates after transplantation were 92.9%, 92.9%, 84.4%, and 75%, respectively. The most striking finding in the study was the high frequency of biliary complications. Another important finding was the significant difference in body mass index (BMI) between pre-transplant and post-transplant (p<0.001). The incidence of rejection and recurrence was 39.1% and 25%, respectively. The number of patients with high anti-tissue transglutaminase (anti-TTG) levels after transplantation decreased significantly (p<0.001). Conclusion: Our study suggests that the frequency of post-transplant biliary complications is very high in CD patients and that LT had positive effects on BMI and anti-tissue transglutaminase levels.
